Vaccination to prevent Mpox Infection (MPOX-VAX Study)

Conditions

Mpox infection

Brief summary

Mean geometric MVA-specific antibody titres at week 48, Mean rate of change in MVA-specific antibody titres post week 6 to week 48

Detailed description

Absolute mean change from baseline in MVA-specific antibody 6 weeks post first vaccine, Neutralising capacity of vaccine-induced immune response for Mpox virus in vitro culture at weeks 6 and 48, Detection of Mpox-specific antibodies at week 0,2,6,12 and 48, Detection of Mpox DNA on anorectal, throat or vaginal swabs at week 0, 2, 6, 12 and 48., Frequency of active STIs at inclusion (HAV (IgM), HBV, HCV, Syphilis, Chlamydia and Gonorrhoea and frequency of participants with chronic HIV infection, HBV or HCV, Incidence of STIs (HAV (IgM), HBV, HCV, HIV, Syphilis, Chlamydia and Gonorrhoea) at week 6,12 and 48

Related papers

No related papers found yet.

Interventions

DRUGIMVANEX suspension for injection Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Mean geometric MVA-specific antibody titres at week 48, Mean rate of change in MVA-specific antibody titres post week 6 to week 48	—

Secondary

Measure	Time frame
Absolute mean change from baseline in MVA-specific antibody 6 weeks post first vaccine, Neutralising capacity of vaccine-induced immune response for Mpox virus in vitro culture at weeks 6 and 48, Detection of Mpox-specific antibodies at week 0,2,6,12 and 48, Detection of Mpox DNA on anorectal, throat or vaginal swabs at week 0, 2, 6, 12 and 48., Frequency of active STIs at inclusion (HAV (IgM), HBV, HCV, Syphilis, Chlamydia and Gonorrhoea and frequency of participants with chronic HIV infection, HBV or HCV, Incidence of STIs (HAV (IgM), HBV, HCV, HIV, Syphilis, Chlamydia and Gonorrhoea) at week 6,12 and 48	—

Measure

Time frame

Absolute mean change from baseline in MVA-specific antibody 6 weeks post first vaccine, Neutralising capacity of vaccine-induced immune response for Mpox virus in vitro culture at weeks 6 and 48, Detection of Mpox-specific antibodies at week 0,2,6,12 and 48, Detection of Mpox DNA on anorectal, throat or vaginal swabs at week 0, 2, 6, 12 and 48., Frequency of active STIs at inclusion (HAV (IgM), HBV, HCV, Syphilis, Chlamydia and Gonorrhoea and frequency of participants with chronic HIV infection, HBV or HCV, Incidence of STIs (HAV (IgM), HBV, HCV, HIV, Syphilis, Chlamydia and Gonorrhoea) at week 6,12 and 48

—

Countries

Ireland

Outcome results

None listed